Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Hao, Wenwei ^a   Zhu, Yongping ^a   Zhou, Huifang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Interleukin 6; Interleukin 8; Laryngeal squamous cell cancer; Prognosis

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; LARYNX SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; KAPLAN-MEIER ESTIMATE; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871406205     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0333-6     Document Type: Article

References (32)

1. Ramroth H, Schoeps A, Rudolph E, Dyckhoff G, Plinkert P, Lippert B, et al. Factors predicting survival after diagnosis of laryngeal cancer. Oral Oncol. 2011;47(12):1154-8.
2. Li XY, Guo X, Feng S, Li XT, Wei HQ, Yang HA et al. Relationship between a family history of malignancy and the incidence of laryngeal carcinoma in the Liaoning province of China. Clinical otolaryngology: official journal of ENT-UK; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery. 2009;34(2):127-31.
3. Ji W, Guan C, Pan Z. Analysis of curative effects on laryngeal carcinoma patients in the northeast region of China. Acta Otolaryngol. 2008;128(5):574-7.
4. Almadori G, Bussu F, Paludettii G. Predictive factors of neck metastases in laryngeal squamous cell carcinoma. Towards an integrated clinico-molecular classification. Acta otorhinolaryngologica Italica: organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale. 2006;26(6):326-34.
5. Gourin CG, Conger BT, Sheils WC, Bilodeau PA, Coleman TA, Porubsky ES. The effect of treatment on survival in patients with advanced laryngeal carcinoma. Laryngoscope. 2009;119(7):1312-7.
6. Johansen LV, Grau C, Overgaard J. Laryngeal carcinoma-multivariate analysis of prognostic factors in 1252 consecutive patients treated with primary radiotherapy. Acta Oncol. 2003;42(7):771-8.
7. Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A. Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev. 2006;32(7):504-15.
8. Nguyen-Tan PF, Le QT, Quivey JM, Singer M, Terris DJ, Goffinet DR, et al. Treatment results and prognostic factors of advanced T3-4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. Int J Radiat Oncol Biol Phys. 2001;50(5):1172-80.
9. Seiler P, Plenz G, Deng MC. The interleukin-6 cytokine system in embryonic development, embryo-maternal interactions and cardiogenesis. Eur Cytokine Netw. 2001;12(1):15-21.
10. Vanden Berghe W, Vermeulen L, De Wilde G, De Bosscher K, Boone E, Haegeman G. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol. 2000;60(8):1185-95.
11. Horn F, Henze C, Heidrich K. Interleukin-6 signal transduction and lymphocyte function. Immunobiology. 2000;202(2):151-67.
12. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989;250(2):607-10.
13. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 1996;15(14):3651-8.
14. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res. 1997;57(1):141-6.
15. Suarez-Cuervo C, Harris KW, Kallman L, Vaananen HK, Selander KS. Tumor necrosis factor-alpha induces interleukin-6 production via extracellular- regulated kinase 1 activation in breast cancer cells. Breast Cancer Res Treat. 2003;80(1):71-8.
16. Barille S, Bataille R, Amiot M. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw. 2000;11(4):546-51.
17. Starska K, Lukomski M, Jozefowicz-Korczynska M, Glowacka E. Production of proinflammatory cytokines IL-6 and IL-8 by peripheral blood lymphocytes T under influence in vitro of squamous cell carcinoma of the larynx. Pol Otolaryngol. 2007;61(4):626-32.
18. Derin D, Soydinc HO, Guney N, Tas F, Camlica H, Duranyildiz D, et al. Serum IL-8 and IL-12 levels in breast cancer. Med Oncol. 2007;24(2):163-8.
19. Konno H, Ohta M, Baba M, Suzuki S, Nakamura S. The role of circulating IL-8 and VEGF protein in the progression of gastric cancer. Cancer Sci. 2003;94(8):735-40.
20. Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol. 2008;19(10):1734-41.
21. Tjiong MY, van der Vange N, ten Kate FJ, Tjong AHSP, ter Schegget J, Burger MP, et al. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecol Oncol. 1999;73(2):285-91.
22. Zhou DH, Trauzold A, Roder C, Pan G, Zheng C, Kalthoff H. The potential molecular mechanism of overexpression of uPA, IL-8, MMP-7 and MMP-9 induced by TRAIL in pancreatic cancer cell. Hepatobiliary Pancreat Dis Int. 2008;7(2):201-9.
23. Vinante F, Rigo A, Vincenzi C, Ricetti MM, Marrocchella R, Chilosi M, et al. IL-8 mRNA expression and IL-8 production by acute myeloid leukemia cells. Leukemia. 1993;7(10):1552-6.
24. Li A, Varney ML, Singh RK. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res. 2001;7(10):3298-304.
25. Chen Y, Shi M, Yu GZ, Qin XR, Jin G, Chen P, et al. Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol. 2012;18(10):1123-9.
26. Liu TR, Xu LH, Yang AK, Zhong Q, Song M, Li MZ, et al. Decreased expression of SATB2: a novel independent prognostic marker of worse outcome in laryngeal carcinoma patients. PLoS ONE. 2012;7(7):e40704.
27. Szczepanik AM, Scislo L, Scully T, Walewska E, Siedlar M, Kolodziejczyk P, et al. IL-6 serum levels predict postoperative morbidity in gastric cancer patients. Gastric Cancer. 2011;14(3):266-73.
28. Alcover J, Filella X, Luque P, Molina R, Izquierdo L, Auge JM, et al. Prognostic value of IL-6 in localized prostatic cancer. Anticancer Res. 2010;30(10):4369-72.
29. Urquidi V, Chang M, Dai Y, Kim J, Wolfson ED, Goodison S, et al. IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol. 2012;12:12.
30. Rubie C, Frick VO, Pfeil S, Wagner M, Kollmar O, Kopp B, et al. Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol. 2007;13(37):4996-5002.
31. Hou T, Tieu BC, Ray S, Recinos A III, Cui R, Tilton RG, et al. Roles of IL-6-gp130 signaling in vascular inflammation. Curr Cardiol Rev. 2008;4(3):179-92.
32. Jee SH, Chu CY, Chiu HC, Huang YL, Tsai WL, Liao YH, et al. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Investig Dermatol. 2004;123(6):1169-75.